Long-term clinical performance of a central venous oxygen saturation sensor for rate adaptive cardiac pacing

Rate Adaptive Pacing: Memories From a Bygone Era

With the recognised physiologic value of dual chamber pacing, there was, at the commencement of the 1980s, an intense search for sensors to enable ventricular pacemakers to alter the pulse repetition rate in response to physiologic demand. Manufacturers fell into two main groups; those who chose highly physiologic sensors often requiring special pacing leads and those whose sensors allowed a standard pacing lead. Thirteen (13) sensors for rate adaptive pacing progressed at least to human investigational studies. Eventually the activity sensor, which responded quickly to exercise, but not to emotional stimuli or pyrexia and used a standard lead would predominate, with all manufacturers eventually accepting what was the least physiologic sensor investigated. The activity-based rate response was not dependent on cardiac or pulmonary disease, which could nullify the response with many of the other sensors. Three (3) other sensors survived that period and are still available today; minute ventilation, closed loop stimulation and central venous temperature, with the first two incorporated with activity as dual sensor systems. This review will outline the development of all the sensors used for rate adaptive pacing.

Development of Implantable Devices for Continuous Ambulatory Monitoring of Central Hemodynamic Values in Heart Failure Patients

BACKGROUND

Care and management of patients with congestive heart failure (CHF) is a major health-care challenge. The value of acute hemodynamic data in assessing heart failure has been questioned in some studies, while more intensive hemodynamic monitoring has been reported to improve patient care in others. A series of patient studies are reported here that were conducted to identify device requirements and verify the feasibility of continuous hemodynamic monitoring in CHF patients and devices for remote transfer and use of these data.

METHODS AND RESULTS

The results of four separate studies in 68 CHF patients who received systems for chronic hemodynamic monitoring between 1992 and the present are reviewed. One early study was with five patients followed for 7-16 months and another study was with nine patients followed for 4-22 months. A third study included 21 patients followed up to 39 months, and the fourth study included 32 patients implanted in 1998-99 with many of them still in follow-up. These studies support the technical feasibility of implanted devices and the external instrumentation required to transfer and manage the collected data. They also support the long-term stability and accuracy of these systems. Three additional acute studies conducted with 30 patients and chronic data from 53 of the 68 patients with the implanted systems are presented that support the feature included in the newer monitors--the ability to reliably estimate pulmonary artery diastolic pressures from the right ventricular pressure signal.

CONCLUSIONS

Development of implantable technology to measure several hemodynamic variables in ambulatory CHF patients is feasible. External instrumentation needed to remotely acquire data from the implanted devices has been verified. The potential to eliminate the uncertainties associated with the use of acute, invasive hemodynamics and the ability to evaluate long-term ambulatory hemodynamic patterns is provided. These findings set the stage for determining the potential clinical value of these systems in impacting the care of chronic CHF patients.

Six years follow-up of an implanted SvO2sensor in the right ventricle

INTRODUCTION

Mixed venous oxygen saturation (SvO(2)) is a standard invasive measure used in the management of congestive heart failure patients. The reliability of a long-term SvO(2) sensor remains unproven.

METHODS

Nine patients (NYHA Class I/II, n=2/7) were implanted with a dual chamber pacemaker modified to utilize a right ventricular SvO(2) lead (Medtronic Inc., Models 8007/4327A IPG/Lead). Invasive studies compared sensor SvO(2) to reference (Optical Swan-Ganz catheter) at 0, 3 and 9 months. Symptom limited tests (Bike(max)) with metabolic assessment and arterial oxygen saturation measurements performed 1-7 days, 3.5 and 9.5 months post-implant allowed for cardiac output calculations. Long-term sensor performance was confirmed by submaximal tests, Bike(subm) in years 1-3, and Walk(in-place) every 6 months for the duration of follow-up.

RESULTS

Sensor SvO(2) readings were stable over time when compared to the Swan-Ganz Catheter. Non-invasive CO measured during Bike(max) was in normal ranges for this patient population, 3.7+/-0.9 l/min at rest and 8.4+/-2.2 l/min at peak-exercise. Resting SvO(2) values from Bike(subm) and Walk(in-place) did not change significantly over time (P>0.1 vs. 1 year) and neither did the change from rest to peak exercise during Bike(subm) (P>0.05 vs. 1 year) or Walk(in-place) (P>0.05 vs. 4 year).

CONCLUSION

While limited in size, this small pilot study suggests that long-term monitoring of SvO(2) by implanted devices may be feasible. The clinical value remains to be proven in future studies.

Cardiac pacing. A review

Pacing is a field of rapid clinical progress and technologic advances. Clinical progress in the 1990s included the refinement of indications for pacing as well as the use of pacemakers for new, nonbradycardiac indications, such as the treatment of cardiomyopathies and CHF and the prevention of atrial fibrillation. Important published data and studies in progress are shedding new light on issues of pacing mode selection, and they may influence future practice significantly. Important technologic advances include development of new rate-adaptive sensors and sensor combinations and the evolution of pacemakers into sophisticated diagnostic devices with the capability to store data and ECGs. Automatic algorithms monitor the patient for appropriate capture, sensing, battery status, and lead impedance, providing better patient safety and pacemaker longevity.

Developments in sensor-driven pacing

This article reviews the recent major developments in the field of rate adaptive pacing. Including, the improved instrumentation of existing sensors, the use of multiple sensors to enhance sensor specificity or sensitivity, and the automation of sensor calibration. The physiologic benefits and programming of rate adaptive pacing are reviewed.

The development of a control method for a total artificial heart using mixed venous oxygen saturation

For physiological control of a total artificial heart (TAH), applying mixed venous oxygen saturation (SVO2) as a parameter for TAH control is a promising approach regarding sensitivity to the recipient's oxygen demand and the practical possibility of continuous monitoring using near infrared rays through transparent blood pump housings. To develop a control method for the TAH using SVO2, the relationship between SVO2 and cardiac output (CO) was investigated in a normal calf, and a control algorithm was developed based on this correlation. Then the feasibility of this method (SVO2 mode) was evaluated in a calf implanted with a pneumatic TAH and compared with the fixed drive control mode (fixed mode) in which the drive parameters were unchanged. The calf performed a graded exercise test in both modes. The CO was effectively increased from 7.3 to 13.0 L/min in the SVO2 mode, and the capacity for exercise was augmented compared to the fixed mode. We conclude that this SVO2 mode is feasible and may be effectively applied in TAH control.

Long-term in vivo experience of an electrochemical sensor using the potential step technique for measurement of mixed venous oxygen pressure

An implantable amperometric blood oxygen sensor was developed to improve rate adaptation of heart pacemakers. Two different working electrode materials in direct contact with the blood were tested, smooth glassy carbon and gold. Reference electrodes of Ag/AgCl and porous pyrolytic carbon were evaluated. A counter electrode being the titanium housing of the pulse generator was partly coated with carbon. An implantable pacemaker system with chronocoulometric oxygen detection was developed. Heart synchronous potential steps were periodically applied to the 7.5 mm2 working electrode in the atrium. Both single and double potential step techniques were evaluated. The oxygen diffusion limited current was used to calculate the stimulation rate. Bench tests and studies on 31 animals were performed to evaluate long-term stability and biocompatibility. In five dogs, the AV node was destroyed by RF ablation to create a realistic animal model of a pacemaker patient. Sensor stability and response to exercise was followed up to a maximum implantation time of 4 years. Post-mortem examinations of the electrode surfaces and tissue response were performed. The results show that a gold electrode is more stable than glassy carbon. The Ag/AgCl reference was found not to be biocompatible, but activated carbon was stable enough for use as reference for the potentiostat. Double potential steps stabilize the sensor response in comparison to single steps. Blood protein adsorption on the gold surface decreased the oxygen transport but not the reaction efficacy. No adverse tissue reactions were observed.

Two-year experience with rate-modulated pacing controlled by mixed venous oxygen saturation

Mixed venous oxy-hemoglobin saturation (MVO2) is a physiological variable with several features that might be desirable as a control parameter for rate adaptive pacing. Despite these desirable characteristics, the long-term reliability of the MVO2 sensor in vivo is uncertain. We, therefore, designed a study to prospectively evaluate the long-term performance of a permanently implanted MVO2 saturation sensor in patients requiring VVIR pacing. Under an FDA approved feasibility study, eight patients were implanted with a VVIR pulse generator and a right ventricular pacing lead incorporating an MVO2 sensor. In order to accurately assess long-term stability of the sensor, patients underwent submaximal treadmill exercise using the Chronotropic Assessment Exercise Protocol (CAEP) at 2 weeks, 6 weeks, and 3, 6, 9, 12, 18, and 24 months following pacemaker implantation. Paired maximal exercise testing using the CAEP was also performed with the pacing system programmed to the VVI and VVIR modes in randomized sequence with measurement of expired gas exchange after 6 weeks and 12 months of follow-up. During maximal treadmill exercise the peak exercise heart rate (132 +/- 9 vs 71.5 +/- 5 beats/min, P < 0.00001) and maximal rate of oxygen consumption (1,704 +/- 633 vs 1382 +/- 407 mL/min, P = 0.01) were significantly greater in the VVIR than in the VVI pacing mode. Similarly, the duration of exercise was greater in the VVIR than the VVI pacing mode (8.9 +/- 3.6 min vs 7.6 +/- 3.7 min, P = 0.04). The resting MVO2 and the MVO2 at peak exercise were similar in the VVI and VVIR pacing modes (P = NS). However, the MVO2 at each comparable treadmill exercise stage was significantly higher in the VVIR mode than in the VVI mode (CAEP stage 1 (P = 0.005), stage 2 (P = 0.04), stage 3 (P = 0.008), and stage 4 (P = 0.04). The correlation between MVO2 and oxygen consumption (VO2) was excellent (r = -0.93). Telemetry of the reflectance of red and infrared light and MVO2 in the right ventricle during identical exercise workloads revealed no significant change over the first 12 months of follow-up (ANOVA, P = NS). The chronotropic response to exercise remained proportional to VO2 in all patients over the first 12 months of follow-up. The time course of change in MVO2 during maximal exercise was significantly faster than for VO2. At the 18- and 24-month follow-up exercise tests, a significant deterioration of the sensor signal with attenuation of chronotropic response was noted for 4 of the 8 subjects with replacement of the pacing system required in one patient because of lack of appropriate rate modulation. Rate modulated VVIR pacing controlled by right ventricular MVO2 provides a chronotropic response that is highly correlated with VO2. This parameter responds rapidly to changes in workload with kinetics that are more rapid than those of VO2. Appropriate rate modulation provides a higher MVO2 at identical workloads than does VVI pacing. Although the MVO2 sensor remains stable and accurate over the first year following implantation, significant deterioration of the signal occurs by 18-24 months in many patients.

Optimal cardiac pacing in patients with coronary artery disease

Pacemaker patients with coronary artery disease and angina pectoris fare better with devices providing AV synchrony and rate increase on exercise provided the programmed upper rate is not excessive. Optimal programming requires knowledge of the factors influencing pacemaker rate response, MVO2 and cardiac sympathetic activity. Inappropriately high rates during rate adaptive pacing can be controlled by new multisensor systems with sensor cross-checking to avoid false positive responses with inappropriate increases in the pacing rate. Permanent pacing in patients with intractable angina who are unsuitable for interventional procedures permits more aggressive pharmacological therapy.

Physiologic control of cardiac assist devices

Total artificial hearts (TAHs) and biventricular assist devices (BVADs) have varying levels of acceptance and reliability, and the research on both focuses on their control mechanisms. Efforts generally aim to achieve a response to physiologic demand and left/right output balance, and beneficial cardiac output (CO) and effective control mechanisms have been achieved by eliciting a Starting-like response to preload and afterload. Such control mechanisms, however, generally base device output on a single parameter, such as the preload on the heart. Current TAHs and BVADs provide relatively fixed oxygen delivery to patients with large physiologically induced variations in oxygen consumption. This paper aims to document fluctuations in oxygen consumption that are normal in BVAD and TAH patients, identify a number of patient-generated signals that reflect these fluctuations, and describe a multitiered control algorithm based upon these signals. Such a control system may offer better response times and more physiologic cardiac outputs. There currently exists a microprocessor-based control mechanism that can be adapted to control TAHs and BVADs using input from a variety of sensors, and it can be found in modern implantable pulse generators (IPGs). Today's pacemakers are capable of rate control and can run diagnostic programs and store data that could be valuable in the evaluation of the patient's condition.

Initial experience with an implantable hemodynamic monitor

BACKGROUND

Measurement of intracardiac hemodynamic parameters has been limited to brief periods in the acute care setting. We developed and evaluated an implantable hemodynamic monitor that is capable of measuring chronic right ventricular oxygen saturation and pulmonary artery pressure.

METHODS AND RESULTS

The device consists of an electronic controller placed subcutaneously and two transvenous leads placed in the right ventricle (reflectance oximeter) and pulmonary artery (variable capacitance pressure sensor). Implantation was performed in 10 patients with severe left ventricular dysfunction. Average implant pulmonary artery pressures were systolic, 52 +/- 16 mm Hg; diastolic, 29 +/- 11 mm Hg; and mean, 40 +/- 12 mm Hg. The mean right ventricular oxygen saturation at implant was 51%. Provocative maneuvers, including postural changes, sublingual nitroglycerin, and bicycle exercise, demonstrated expected changes in measured oxygen saturation and pulmonary artery pressures over time. At follow-up of 0.5 to 15.5 months, there were no significant differences between pulmonary artery pressures or oxygen saturation values transmitted from the device and simultaneous measurement with balloon flotation catheters. Four of the pulmonary artery leads dislodged and three demonstrated sensor drift, whereas two of the oxygen saturation sensors failed. Four patients died and four received transplants. Pathological study did not demonstrate injury to the right ventricular outflow tract or pulmonic valve.

CONCLUSIONS

Chronic measurement of hemodynamic parameters in the outpatient setting with implantable sensor technology appears to be feasible. The devices are well tolerated without significant untoward effects, and the sensors generally function well over time, providing reliable information. Clinical usefulness remains to be established.